### **SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

	M		

	FORIVI	2U-F
(Mark One)		
	REGISTRATION STATEMENT PURS OF THE SECURITIES EX	
X	ANNUAL REPORT PURSUANT TO SECURITIES EXCHA For the fiscal year ende	NGE ACT OF 1934
	or TRANSITION REPORT PURSUANT SECURITIES EXCHA	• •
	Commission File N	lumber: 1-15096
	SERON	
	(Exact name of Registrant a	s specified in its charter)
	Not Applicable	Switzerland
(Translation o	f Registrant's name into English)	(Jurisdiction of incorporation or organization)
	15 bis, Chemi Case Pos CH-1211 G Switzer (Address of principal	tale 54 eneva 20 land
	Securities registered pursuant	to Section 12(b) of the Act:
	itle of each class:	Name of each exchange on which registered:
Bearer Shares	, nominal value CHF25 per share	New York Stock Exchange*
	(as evidenced by American Depositary one fortieth of a Bearer Share	New York Stock Exchange
*Not for trading, but only in co	onnection with the registration of American Deposit	ary Shares, pursuant to the requirements of the Securities and Exchange
	Securities registered pursuant Nor	***
	Securities for which there is a reporting oblig	• • • • • • • • • • • • • • • • • • • •
Indicate the number of	outstanding shares of each of the issuer's classes	of capital or common stock as of December 31, 2003.
Bearer Shares, nomina	l value CHF 25 per share:	11,406,887 outstanding
Registered Shares, nor	ninal value CHF 10 per share:	11,013,040 outstanding
	months (or for such shorter period that the registra	uired to be filed by Section 13 or 15(d) of the Securities Exchange Act of ant was required to file such reports), and (2) has been subject to such filing
		⊠ Yes □ No
Indicate by check mark	which financial statement item the registrant has e	lected to follow.





# Page 3 of 231

### Serono S.A. Annual Report on Form 20-F for the year ended December 31, 2003

### **TABLE OF CONTENTS**

Item		Page No.
	PART I	
1.	Identity of Directors, Senior Management and Advisers	1
2.	Offer Statistics and Expected Timetable	1
3.	Key Information	1
4.	Information on the Company	13
5.	Operating and Financial Review and Prospects	36
6.	Directors, Senior Management and Employees	52
7.	Major Shareholders and Related Party Transactions	60
8.	Financial Information	61
9.	The Offer and Listing	64
10.	Additional Information	64
11.	Quantitative and Qualitative Disclosures about Market Risk	72
12.	Description of Securities Other than Equity Securities	75
	-i-	



## Page 4 of 231

Item		Page No.
	PART II	
13.	Defaults, Dividend Arrearages and Delinquencies	76
14.	Material Modifications to the Rights of Security Holders and Use of Proceeds	76
15.	Controls and Procedures	76
16A.	Audit Committee Financial Expert	76
16B.	Code of Ethics	76
16C.	Principal Accountant Fees and Services	76
	PART III	
17.	Financial Statements	78
18.	Financial Statements	78
19.	Exhibits	78
	SIGNATURES	
	<u>Signatures</u>	79
	Financial Statements and Auditors' Reports	F-1

The registered (®) and the filed (™) trademarks and the filed service marks (SM) Cetrotide™, click.easy®, cool.click®, Crinone®, EasyJect®, Ferti.net®, Fertinex®, Geref®, Gonal-f®, GHMonitor<sup>SM</sup>, Howkidsgrow<sup>SM</sup>, Luveris®, Metrodin HP®, MSLifelines<sup>SM</sup> Novantrone™, one.click®, Ovidrel®, Ovidrel®, Pergonal®, Profasi®, Raptiva™, Rebif®, Rebiject®, Rebiject II®, Reliser®, Saizen®, SeroJet™, Serono®, Serophene®, Serostim®, Stilamin® and Zorbtive™, as well as the filed trademarks (™) for the "S" symbol, used alone or with the words "Serono" or "Serono biotech and beyond," are trademarks of, or are licensed to a subsidiary of, Serono S.A. Trade names and trademarks of other companies appearing in this report are the property of their respective owners.

### **PART I**

#### Item 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

Not applicable.

### Item 2. OFFER STATISTICS AND EXPECTED TIMETABLE

Not applicable.

#### Item 3. KEY INFORMATION

### **Selected Consolidated Historical Financial Data**

We have derived our selected consolidated historical financial data from our consolidated financial statements. We prepare and present our consolidated financial statements in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB, and its predecessor organization, the International Accounting Standards Committee. IFRS differ in significant respects from United States Generally Accepted Accounting Principles, or U.S. GAAP. You can find a reconciliation of our audited consolidated financial statements to U.S. GAAP in Note 34 to our audited consolidated financial statements included in this Annual Report. Since the information we present below is only a summary and does not provide all of the information contained in our consolidated financial statements, you should read our consolidated financial statements and the notes to the consolidated financial statements included in this Annual Report.

	Year ended D	Year ended December 31,		
	2003 2002 20	001 2000 1999		
	(U.S. dollars in thousand	s, except per share data)		
Income Statement Data:				
Product sales	\$ 1,858,009 \$ 1,423,130 \$ 1,24			
Royalty and license income	160,608 114,705 12	27,065 92,656 78,40		
Total revenues	2,018,617 1,537,835 1,37	76,470 1,239,654 1,132,54		
Operating expenses:				
Cost of product sales	279,619 223,751 2 <sup>-</sup>	13,160 229,907 260,74		
Selling, general and administrative	636,823 504,248 44	16,945 393,716 369,74		
Research and development, net	467,779 358,099 30	08,561 263,152 221,62		
Restructuring	— 16,303			
Other operating expense, net	199,476 85,811 7	70,152 31,147 58,71		
Total operating expenses	1,583,697 1,188,212 1,03	38,818 917,922 910,84		
Operating income		37,652 321,732 221,70		
Financial income, net		51,381 52,277 2,45		
Other expense, net	19,743 1,658	2,548 2,411 1,07		
Total non-operating income, net	24,275 34,818	18,833 49,866 1,38		
Income before taxes and minority interests	459,195 384,441 38	36,485 371,598 223,08		
Taxes	68,905 63,127	69,816 70,384 39,77		
Income before minority interests	390,290 321,314 3 <sup>-</sup>	16,669 301,214 183,30		
Minority interests	327 536	(52) 174		
Net income	\$ 389,963 \$ 320,778 \$ 3 <sup>-1</sup>	16,721 \$ 301,040 \$ 183,29		
Per Share Data:				
Basic income per share (1)(2):				
Bearer shares	\$ 24.63 \$ 20.07 \$	19.72 \$ 19.50 \$ 12.2		
Registered shares	9.85 8.03	7.89 7.80 4.8		
American depositary shares (3)	0.62 0.50	0.49 0.49 0.3		



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

## **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

